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Abstract: Background: Breast cancer is a type of cancer that has a high prevalence, can occur in men and women
C,,tokines are factors that are knora? to have good properties of tumor groMh and tumor inhibitory effects. Cyokine has an
important role in the control ofthe immune system. development ofbreast carcinoma is closely related to mRNAexpression of
IL-6 as pro-inflammatory cytokine and mRNA expression oflL-10 as antiinflammatory cltokine. Purpose: Examine changes
in mRNA expression of proinflammatory cytokine and antiinflammatory cytokine in breast cancer patients with or without
chemotherapy. Method: This is a case-control study, 12 subjects with breast cancer with chemotherapy as case group and 12
subjects with breast cancer without chemotherapy as control group. ln this study we using PCR and RFI,P techniques to detect
polymorphisms in IL-6 and IL-10 gene. Results: In RFLP analysis, found that IL-6 and IL-10 gene were not polymorphic in all
subjects for both case and control groups. Mean value of IL-6 mRNA on breast canc€r patients without receiving
chemotheraphy was 10.84+0.48 whereas on breast cancer patients with chemotherapy was 6.28+1.19. Mean value ofIL-10
mRNA on breast cancer patients without receiving chemotheraphy was 6.76+0.81 whereas on breast cancer palients with
chemotherapy was 9.81+l.07. The mean value of IL-6 rhRNA on breast cancer patients without receiving chemotheraphy was
statistically signihcant higher than in patients with chemotheraphy. In contrast, mean value of IL-I0 mRNA on breast cancer
patients without receiving chemotheraphy was statistically significant lower than in patients with chemotherapy. Conclusion:
Combination of chemotherapy docetaxel, adriamycin, cyclophosphamide cause a decrease in mRNA expression of lL-6 and an
increase in the expression of mRNA of IL-10 in patients with breast cancer.
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Breast cancer is a type of cancer that has a high prevalence
in the world . lt is estimated that in 2012 the world's incident
1,676,633 cases wirh mortality 521,817. ln Asia Pacific
region estimated 403,876 cases of breast cancer with a
mortality rate of 115,863. ln Southeast Asia estimated
107,545 cases with a mortality ftte 42,003. In Indonesia
48.998 cases of breast cancer with a mortality rate 19.750 [1].
Breast cancer is a heterogeneous disease with numerous
genetic, molecular and cellular characteristics t2l
Interleukins play a major role in many solid cancers
pathogenesis. Polymorphisms in interleukins genes are
thought to influence the expression or ftnction of these
proteins and many have been evaluated for their role in
inflammatory disease and cancer predisposition [3].
Interleukins are regulatory proteins that modulates immune
response by stimulating or inhibiting the activation,
proliferatiorl and/or diferentiation of target cells. Different
lnterleukins are known to have diverse role in breast cancer
initiation and progression [4].
Elevated interleukin 6 (IL-6) and interleukin l0 (L-10)
serum concentration, are strongly associated with breast
cancer and correlate with clinical stage of disease.
lnterleukins may stimulate cancer cells growth and contribute
to locoregional relapse as well as metastasis [5].
The interleukin-6 (IL-6) plavs an important role in the
process of inflamm 
^tion, 
partiulady in the transition from
acute to chronic inflammation. In breast cancer, IL-6 has
b€en shown to inhibit the growth of cancer cells but promote
the development of metastases [6] [7]. Interleukin-I0 is a
multifunctional cytokine with both immunosuppressive and
antiangiogenic functions. Intedeukin 10 is a potent
immunoregulatory cytokine. Ir inhibits some cell functions,
including T-helper (Thl) cell activity, and stimulates other
functions such as a natural killer (NK) activity [8].
Polymorphisms in the IL-10 gene promoter genetically
determine the differences in IL-10 production [9] [8].
Interleukin-10 is an immunosuppressive cytokine which
responsible for development of canc€r by suppo.ting tunor
escape from the immune respons€ [0]. Interleukin- 10 may
be regulated by a complex monoctte and macrophage-
derived c)'tokine network and an impairment of the immune
system can be observed in neoplastic disease [1].
The aim of this study was to evaluate mRNA expression
and polymorphism of interleukin-6 and Interleukin- l0 in a
case control model to determine any associations with breast
cancer patients chemotheraphy.
2. Materials and Method
2. I . (blleclioa of Samples
A matched case-control study was conducted within a
population of breast cancer patients who had been diagnosed
through clinical and histopathology examination, which
entered the Prol Dr RD. Kandou Hospital and Network
education hospitals in Manado, North Sulawesi, Indonesia.
AII samples who fulfilled inclusion and exclusion criteria and
willing to participate in the study and signing informed
consent. The case group mnsisted of 12 patients with breast
cancer who have undergone combinations chemotherapy(combination of docetaxel, adriamycin and
cyclophosphamide). The control group was 12 patients with
breast cancer who did not receive any chemotherapy.
2,2. Nucleic Acid Isolrtion
Nucleic acid was extracted fiom breast cancer tissue
according to the diatom guanidinium isothiocyanate (GuSCN)
method described by Boom et al. 1990. Breast cancet tissue
was mixed with 500p1 of lysis buffer L6 (50mMTris-HCl,
5.25M GuSCN,20mM EDTA 0.1% Triton xl00), vortexes
vigorously, and centrifuged at 1,000 rpm for 5min. To obtain
the nucleic acid, samples were lysed by incubation for 15
minutes at l8'C and 20tl of diatom suspension was added
The diatom containing the bound nucleic acid was
centrifuged at 12,000 x g for l5 seconds to obtain diatom
pellet. The diatom pellet was then washed with washing
buffer L2 (5.25M GuSCN in 0.lM Tris-HCI, pH6.4), rinsed
with 70o/o ethanol and acetone, and dried byincubation at
56"C for l0 minutes. The pellet was mixed with 609l of
l0mM Tris-HCl, pH 8.Q lmM EDTA buffer and fte nucleic
acid was eluted by incubation at 56"C for l0 minutes. After
sedimentation of the diatom by centrifugation, the
supematant was collected and stored at -20'C until Real-
Time PCR was performed [ 2].
2,3. Polymorphisms ol IL6 and IL10 Genes by RFLP-P|JR
Method
Deteclion of polymorphisms IL-6 and lL-10 genes was
done according to RFLP PCR [3]. Primer set for IL6 gene
were used IL6 F: 5'-GGAGTCACACACTCCACCT-3' and
IL6 R: 5'-CTGATTCTGAAACCTTATTAG-3' with enzyme
restriction is Nla IlL Primer set for IL [0 gene were use ILlo
F: 5'-CTCACTATAAA,A,T{TAGAGACGG -3); IL10 R : C
(5'-CTGGCTTCCTACAGG- 3) allel; ILl0 R : A (5'-GAC
TC'CTCTTCCTACAGT-3') allel with restriction enzyme Ssp I.
All PCR product were run in lo% agarose gel electrophoresis
and visualized by ultraviolet light.
2.1. Expression nRNA IL6 and IL6 Genes by Real Ttme
PCR
Deteclion of mRNA expression of IL6 and ILIO was done
according to Real time PCR method previously describe by
Arnapaula Q 20ll and Yajima I 1998 Il4, l5l. Speciltc
primers for mRNA lL-6 were used IL-6 forward:
CTGTTGACAAGCAATGAGACGATGAGG and IL-6
reverse: GAGGATACCACTCCCAACAGACC. Cycle RT
PCR for IL-6 was 94'C for 3 minute; 94"C for 30 second 38
cycles and next step is PCR: 5l'C for 30 second; 72oC for 30
second. Specific primers for ILl0 were used primer ILIO
forward: GGTTGCCAAGCCTTATCGGA and IL 10 Dan IL
l0 reverse: ACCTGCTCCACTGCCTTGCT. Cycle RT PCR
for IL-6 was 94oC for 3 minute;94'C for 30 second for 32
cycles arrd next step is PCR: 52oC for 30 second; 72"C for 4O
second. Also, specific primers of GAPD were used GAPDH
forward: AGAGGGAAATCGTGCGTGAC and GAPDH
reverse : CAATAGTGATGACCTGGCCGT.
2.5. DataAnalysis
Data analysis using the SPSS (Statistical Package for
Social Science) version 22
2.6. Ethical Clcarence
Ethical approval for this study was obtained from Research





During the period from January to February 2015 acquired
research zubjects were 24 patients with breast cancer which
meet the inclusion criteria. Within 24 patients with breast
cancer consisted of 12 patients breast cancer that have not
received chemotherapy and 12 patients who had neoadjuvant
chemotherapy or adjuvant combination docetaxel with
adryamicin and cyclophosphamide. Minimum age of subject
was 38 years and maximum was 67 years old, the mean age
of subjects in this research was 52.5 years. Within 24 subject
in this research there were l7 subject found in stage III (A / B)
and 7 patients with stage IV. In RFLP analysis, found that IL-
6 and IL-10 gene were not polymorphic in all subject for
both case and control groups.
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Figure 5 shows the mean of IL-6 mRNA expression was
lower in breast cancer patients who have received
chemotherapy compared to the mean mRNA expression of
IL-6 in breast cancer patients without chemotherapy. Figure 6
shows the mean IL-10 mRNA expression was higher in
patients who have received chemotherapy than the mean of
nRNA expression of IL-10 in breast canc€r patients without
ch€motherapy.
Mean value of IL-6 mRNA on breast cancer patients
without receiving chemotheraphy was 10.84*0.48 whereas
on breast cancer patients with chemotherapy was 6.28+1.19
shown in table L Mean value of IL-10 mRNA on breast
cancer patients without rec€iving chemotheraphy was
6.76+0.81 whereas on breast cancer patients with
chemotherapy was 9.81+1.07 shown in table L The mean
value of IL-6 mRNA on breasl canc€r patients without
receiving chemotheraphy was statistically significant higher
than in patients with chemotheraphy (p<0.001). In contrast,
mean value of IL- I 0 rnRNA on breast cancer patients without
receiving chemotheraphy was statistically significant lower
than in patients with chemotherapy (p<0.001). The
magnitude ofthe difference in average nRNA expression of
IL-6 was 4.84 or mRNA expression of IL-6 in the
chemotherapy group had 43.8 % lower than the group
without chemotherapy (Table l) The magnitude of the
difference in average mRNA expression of IL- l0 was 3.05 or
mRNA expression of IL-10 in the chemotherapy group had
45.3 9/o highet than the group without chemotherapy (Table
r).
American Journal of Clinical and Experimental Medicine
2015: X(X):XX-XX
Published online MM DD,2015 (http://r.r'wv'.sciencepublishinggroup.com/j/ajcem)
doi: 1 0. I I 648/j.)O(XX.20 I 5)O(XX. XX
ISSN: 2330-8125 (Print); ISSN: 2330-8133 (Online)
J:ier: e-? a
frhxr DrHhllry 0rul
Ttrblc I. Conparison expression nRNA erpression of IL-6 in Breast Corcer
palients wilhoilt otd afler chemotherapv.
Breast Cancer patients
cancer cell prolit-eration and gowth are reduced after
treatment. This study supported by other study on prostate
cancer, reported that significant association between high IL-
6 in sera of prostate cancer patients and decreased response
to docetaxel [23].
In this study, mean value of IL-10 mRNA on breast cancer
patients without receiving chemotheraphy was statistically
significant lower than in patients with received chemotherapy.
Interleukin 10 is a potent cytokine, inhibits some cell
functions, including T-helper cell activity and stimulates
natural killer activity. In a murine model study suggested that
IL-10 has antitumor and antimetastitic properties in mice,
possible use of IL-10 in the treatment of human metastatic
cancers [8]. Study on Interleukin-12 and interleukin-10
production by mononuclear phagocytic cells from breast
cancer patients show that mononuclear cells of patients
aflbcted by breast cancer have a defbctive IL-12 production
capability while generating higher amounts of IL-10 [ l].
In this study we concluded that combination of
chemotherapy docetaxel, adriamycin, cyclophosphamide
cause a decrease in mRNA expression of IL-6 and an
increase in the expression of mRNA of IL- l0 in patients with
breast cancer.
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which are stimulators of angiogenesis as well as factors for








and antitumor activities of interleukin l0 in a murine rnodel of
breast cancer. Journal of the National Cancer Institute 1996,
88{8):536-541.
Kong F, Liu J. Liu I Song B, Wang H, Liu W: Association of
interleukin-I0 gene polymorphisms with breast cancer rn a
Chinese population. Joumal of experimental & clinical cancer
research . CR 2010, 29'.72.
Woo SU. Bae JW, Yang JH. Kim JH- Nam SJ. Shin YK:
Overexpression of interleukin-IO in sentinel lyrnph node with
breast cancer. Annals ofsurgical oncology 2007, 14(ll):3268-
3273.
Merendino RA, Gangemi S, Misefari A, Arena A, CapozzaLB,
Chillemi S, D'Ambrosio FP: Interleuliin-|2 and interleukin-10
production by mononuclear phagocytic cells from breast
cancer patients. Immunology lettsrs I 999, 68(2-3): 3 5 5 -35 8.
Boom R SC, Salimans MM, Jansen CL, Wertheim-van
DllenPM. van der Noordaa J.: Rapid and simple method
forpurification of nucleic acids. J ClinMicrobiol 1990,
29(496-s03\.
Camil L. Bohiltea, Radoi. VE: Interleukin-6 and interleukin-
l0 gcnc polymorphisms and rccurrcnt prcgnanc;- loss in
Romanian population. kan J Reprod Md 2014, 12(9):617-
622.
Arurapaula Gulietti. Lut Overbergh, Dirk Valck, Brigitte
Decallonne, Roger Bouillon, Mathieu C: An Overvierv of
Real-Time Quantitative PCR: Applications to Quantify
Cltokine Gene Expression. . Methods 2001.25:38G401.
Yajima I Atsuhito Yagihashi, Daisuke Furuya, Kameshim H:
Quantitative reverse transcription-PCR assay of the RNA
component of human telomerase using the TaqMan
fluorogenic detection system. Clinical chemistrr" 1998,
441L2\'.2441-2445.
Marklcula A, Simonsson M, Ingvar C, Rosc C, Jsnstrom H:
IL6 genoffie, tumour ER-status, and treatment predicted
disease-free survival in a prospective breast cancer cohort.
BMC cancer 2014. 14:759
Cherel M, Campion L. Bezieau S. Campone M, Charrier J,
Gaschet J, Ricolleau G Gouraud W, Charbonnel C, Jezequel P:
Molecular screening of interleukin-6 gene promoter and
inlluence of -l74GlC polymorphism on breast cancer.
Cytokine 2009, 47 (3):211-223.
DarZJ, Wang XJ, ZhaoY, Ma XB, Kang HF, Min WL, Lin S,
Yang PT, Liu XX: Effects of interleukin-IO pollmorphisms
(rs1800896, rs1800871. and rs1800872) on breast cancer risk:
evidence from an updated meta-analysis. Genetic testing and
molecular biomarkers 2014. l8(6):439445.
Gordani L,BruzA P, Lasalandra C, Quaranta M, Schittulli F.
Della Ragione F, Iolascon A: Association of breast cancer and
polymorphisms of interleukin-l0 and tumor necrosis factor-
alpha genes. Clinical chemistry 2003, 49( 1 0): l 6g- 1667 .
Yu KD, Chen AX, Yang C, Fan L, Huang AJ, Shao ZM: The
associations bctwccn two polymorphisms in thc intcrlcukin-10
gene promoter and breast cancer risk. Breast cancer research
and treatrnent 20 12, 13 l(1):27 -3 l.
Lis CG, Grutsch JF, Vashi PG, CA. L: Is serum albumin an
independent predictor of survival in patients with breast
cancer? J Parenter Enteral Nutr 2003. 27:10-15
Cho YA. Sung MK, Ymn JY Ro J, Kim J: Propostic role of
interleukin-6, interleukin-8, and leptin levels according to
breast cancer subt1pe. Cancer research and treatment : ofhcial
journal of Korean Cancer Association 20 I 3. 45(3):2 I 0-2 I 9.
[23] Domingo-Domenech J, Oliva C, Rovira A, Codony-Sen'at J,
Bosch M. Filella X, Montagut C, Tapia M, Campas C, Dang L
et ai: interleukin 6, a nuciear factor-kappaB target, predicts
resistaoce to docetaxel in hormone-independent prostato
cancer and nuclear factor-kappaB inhibition b.v PS-1145
enhances docetarel antitumor activity. Clinical cancer
research : an offrcial journal of the American Association for
Cancer Research 2006. l2(1 8):5578-5586.
li6l
[1 7]
ll8l
[1e]
[20]
[2 l]
[22]
7
